- Home
- IQ vs BLTE Comparison
IQ vs BLTE Comparison
Compare IQ & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQ
- BLTE
- Stock Information
- Founded
- IQ 2009
- BLTE 2018
- Country
- IQ China
- BLTE United States
- Employees
- IQ N/A
- BLTE N/A
- Industry
- IQ Consumer Electronics/Video Chains
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- IQ Consumer Discretionary
- BLTE Health Care
- Exchange
- IQ Nasdaq
- BLTE Nasdaq
- Market Cap
- IQ 2.5B
- BLTE 2.1B
- IPO Year
- IQ 2018
- BLTE 2022
- Fundamental
- Price
- IQ $2.65
- BLTE $66.90
- Analyst Decision
- IQ Strong Buy
- BLTE Strong Buy
- Analyst Count
- IQ 5
- BLTE 4
- Target Price
- IQ $2.61
- BLTE $96.00
- AVG Volume (30 Days)
- IQ 24.0M
- BLTE 42.1K
- Earning Date
- IQ 08-20-2025
- BLTE 11-11-2025
- Dividend Yield
- IQ N/A
- BLTE N/A
- EPS Growth
- IQ N/A
- BLTE N/A
- EPS
- IQ 0.01
- BLTE N/A
- Revenue
- IQ $3,863,007,761.00
- BLTE N/A
- Revenue This Year
- IQ N/A
- BLTE N/A
- Revenue Next Year
- IQ $3.79
- BLTE N/A
- P/E Ratio
- IQ $273.35
- BLTE N/A
- Revenue Growth
- IQ N/A
- BLTE N/A
- 52 Week Low
- IQ $1.50
- BLTE $43.70
- 52 Week High
- IQ $3.35
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- IQ 53.57
- BLTE 51.95
- Support Level
- IQ N/A
- BLTE N/A
- Resistance Level
- IQ $2.84
- BLTE $69.90
- Average True Range (ATR)
- IQ 0.11
- BLTE 2.18
- MACD
- IQ -0.12
- BLTE -2.22
- Stochastic Oscillator
- IQ 93.31
- BLTE 95.71
About IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.